{"id":"W2898394782","doi":"10.1093/annonc/mdy424.045","title":"KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Carboplatin; Head and neck squamous-cell carcinoma; Internal medicine; Pembrolizumab; Interim analysis; Cisplatin; Phases of clinical research; Oncology; Chemotherapy; Gastroenterology; Head and neck cancer; Radiation therapy; Nuclear medicine; Randomized controlled trial; Urology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004082857,0.0001879612,0.0007676615,0.0001801164,0.00007985951,0.00000415995,0.0001159713,0.0001000219,0.0001381624],"category_scores_gemma":[0.00009892465,0.0001601527,0.0001442064,0.0001985664,0.0002988804,0.00004930494,0.00004421427,0.0001036228,0.000002114917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003550435,"about_ca_system_score_gemma":0.0001902162,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005555235,"about_ca_topic_score_gemma":0.001055178,"domain_scores_codex":[0.9984479,0.00008383996,0.000681516,0.0003060027,0.0001692401,0.0003114794],"domain_scores_gemma":[0.99848,0.0002807039,0.0003851193,0.0003231382,0.000419747,0.0001112614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4214385,0.04050143,0.01801697,0.002117848,0.0008663774,0.0001261262,0.01633296,0.000002889051,0.02250151,0.00005538638,0.03297477,0.4450652],"study_design_scores_gemma":[0.2597142,0.5510615,0.02535403,0.0001488331,0.000774984,0.000135673,0.002729718,0.0006938257,0.04384604,0.000215447,0.1149018,0.0004239979],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934772,0.002360011,0.0000662443,0.001275097,0.0003000738,0.001383104,0.00006831669,0.00001453799,0.001055362],"genre_scores_gemma":[0.9984374,0.0002367194,0.0002818513,0.0005323643,0.0001736301,0.00006432144,0.00002483606,0.00002357613,0.0002253229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5105601,"threshold_uncertainty_score":0.6530837,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1053882196610361,"score_gpt":0.416188050832784,"score_spread":0.3107998311717479,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}